Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30055084 | 1.00 | KMT2A (0.52) | KMT2AMAPK1ALDH1A1STAT3CYP1A2 | |
| SCHEMBL3707631 | 0.74 | KMT2A (0.53) | KMT2AALDH1A1STAT3CYP1A2CYP2C9 | |
| SCHEMBL11382345 | 0.69 | KMT2A (0.70) | KMT2AMAPK1ALDH1A1HSP90AA1NPSR1 | |
| SCHEMBL10785394 | 0.67 | KMT2A (0.61) | KMT2AMAPK1ALDH1A1HSP90AA1NPSR1 | |
| SCHEMBL4901236 | 0.65 | TLR9 (0.49) | MAPK1ALDH1A1TLR9HSP90AA1ATM | |
| SCHEMBL13056396 | 0.64 | TLR9 (0.74) | KMT2AMAPK1ALDH1A1TLR9HSP90AA1 | |
| SCHEMBL79589 | 0.64 | MAPK1 (0.54) | KMT2AMAPK1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL29354362 | 0.64 | MAPK1 (0.54) | KMT2AMAPK1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL27512460 | 0.64 | KMT2A (0.50) | KMT2AMAPK1ALDH1A1STAT3CYP1A2 | |
| SCHEMBL19381727 | 0.63 | KMT2A (0.48) | KMT2AALDH1A1STAT3CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2012-06-07 | — | — | US | claimed |
| EP-2448965-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2012-05-09 | — | — | EP | claimed |
| WO-2011000095-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-01-06 | — | — | WO | claimed |
| EP-3925969-B1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS SEC (CA) | 2025-09-03 | — | — | EP | disclosed |
| EP-3925969-A1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | Transfert Plus, S.E.C. (CA) | 2021-12-22 | — | — | EP | disclosed |
| EP-3380495-B1 | PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY | TRANSFERT PLUS SEC (CA) | 2021-05-19 | — | — | EP | disclosed |
| EP-2391218-B1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SMARTCELLS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2018-01-18 | — | — | US | disclosed |
| US-9745355-B2 | Binding-site modified lectins and uses thereof | SMARTCELLS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088294-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088300-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-1019721-B1 | CHROMOPHORES IN THE PREPARATION OF NOVEL TANDEM CONJUGATES | BECTON DICKINSON CO (US) | 2007-06-13 | — | — | EP | disclosed |
| US-6372445-B1 | Chromophores in the preparation of novel tandem conjugates | BECTON DICKINSON AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| EP-1019721-A1 | CHROMOPHORES IN THE PREPARATION OF NOVEL TANDEM CONJUGATES | Becton Dickinson and Company (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999018437-A1 | CHROMOPHORES IN THE PREPARATION OF NOVEL TANDEM CONJUGATES | BECTON DICKINSON AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10398781-B2 | Conjugate based systems for controlled drug delivery | SI, CSGALNACT1, CD44 | KMT2A 3261/4885MAPK1 4735/4885ALDH1A1 705/4885 |
| US-20120141416-A1 | MULTIMERIC PEPTIDE CONJUGATES AND USES THEREOF | LNPEP, DNPEP, VIP | KMT2A 3839/4885MAPK1 3495/4885ALDH1A1 4126/4885 |
| US-20180015180-A1 | SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND USES THEREOF | SLC43A1, SLC7A5, DNPEP | KMT2A 2621/4885MAPK1 3098/4885ALDH1A1 2517/4885 |
| US-20180064824-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY | SI, CSGALNACT1, CD44 | KMT2A 3261/4885MAPK1 4735/4885ALDH1A1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.